Join Our Network

• Have at least three of the following technologies
  • MPOD
  • Fundus Photography
  • OCT/OCT-a
  • Dark Adaptation Testing- AdaptDx® or AdaptDx Pro®
  • In office CCTV demonstration
  • Prescribes ForeseeHome® AMD Monitoring program for intermediate dry AMD patients
• Accomplished at least one of the following:
  • Given a lecture on AMD or low vision at a professional meeting in the last 18 months
  • Published an article on AMD or low vision within the last 18 months
  • Presented an AMD talk to a patient group within the last 18 months
  • Fellow in good standing of the ORS
  • Fellow in good standing of AAOptom
  • Fellow in good standing of OWNS
  • Obtained at least 3 hours of COPE approved AMD education in the last 18 months

• Physicians treating AMD should be fellowship trained in retina, board certified in ophthalmology, and members in good standing of both American Society of Retina Specialists (ASRS) and American Academy of Ophthalmology (AAO).
• Facility should have all applicable diagnostic testing equipment available at the physical site:
  • Spectral-domain or swept-source OCT device
  • Fundus photography
  • Autofluorescence
  • Fluorseceein angiogram
  • Diagnostic testing equipment

Each physician/facility should meet at least two of the following conditions:

• At a minimum, at least 30% of the practice should be AMD patients
• Participate in a multicenter study investigating a new treatment for AMD
• Lecture on AMD
• Author a paper or publication on AMD
• Prescribes ForeseeHome® AMD Monitoring program for intermediate dry AMD patients

All physicians agree to have available the following medications:

• • Bevacizumab (Avastin, Genentech)
  • Ranibizumab (Lucentis, Genentech)
  • Faricimab-svao (Vabysmo, Genentech)
  • Ranibizumab (Susvimo, Genentech)
  • Aflibercept (Eylea, Regeneron)
  • Brolucizumab-dbll (Beovu, Novartis)
  • Any new anti-vascular endothelial growth factor (VEGF)/similar medication approved by the FDA and Medicare.